A spoonful of sugar: The risks of negative health outcomes of polypharmacy in MS is a bitter reality

Abstract

Get full access to this article

View all access options for this article.

References

Chertcoff

Zhu

, et al. Polypharmacy and multiple sclerosis: A population-based study. Mult Scler J. Epub ahead of print 27 October 2022. DOI: 10.1177/13524585221122207.

World Health Organization. Medication safety in polypharmacy. Geneva: World Health Organization, 2019.

Bourdette

Herink

Polypharmacy in multiple sclerosis: More is not necessarily better. Mult Scler. Epub ahead of print 14 October 2022. DOI: 10.1177/13524585221129964.

Thelen

Zvonarev

Lam

, et al. Polypharmacy in multiple sclerosis: Current knowledge and future directions. Mo Med 2021; 118(3): 239–245.

Frahm

Hecker

Zettl

UK.

Polypharmacy among patients with multiple sclerosis: A qualitative systematic review. Expert Opin Drug Saf 2020; 19(2): 139–145.